Five treatments. No incision. Eight years of receipts. For decades, the surgery-versus-radiation conversation in localized prostate cancer ran on retrospective series and conviction. PACE-A changed the evidence base: it's the first phase 3 trial to randomize men between modern prostatectomy and five-fraction SBRT — and the 8-year results, presented at ASTRO 2026, are the ones that matter. The cancer control: 123 men, 8 UK centers, low- to favorable intermediate-risk disease; SBRT 36.25 Gy in 5 fractions; no hormone therapy in either arm. Freedom from biochemical or clinical failure at 8 years: 91% (SBRT) vs. 84% (surgery) — NOT statistically significant, and the trial was not powered to prove equivalence. Not one man in either arm died of prostate cancer. The function gap is where the trial actually speaks: urinary pad use at 5 years was 8% after SBRT vs. 48% after surgery, and median erectile-function score was 19 vs. 5 on a 25-point scale. As PI Nicholas van As put it, patients previously had to choose "without randomized evidence directly comparing the treatments. PACE-A changes that." When cancer control is this close and mortality this low, the decision doesn't belong to the survival curves — it belongs to the patient's priorities: continence, sexual function, treatment burden. Our job is to present both columns honestly, including the statistical tie at the top.

They treated every metastasis they could see. It didn't matter. NRG-BR002 just delivered one of the most sobering results in recent radiation oncology: in oligometastatic breast cancer, ablating every visible metastasis with SBRT or surgery — on top of first-line systemic therapy — did NOT improve progression-free or overall survival. The numbers: • 125 patients, 4 or fewer metastatic lesions, 47 institutions across the US and Canada • Median PFS: 23 months (systemic therapy alone) vs. 19.5 months (systemic + ablation of all known sites) • Overall survival: no significant difference • Longer follow-up: still no PFS benefit, no reduction in new metastases elsewhere Read that again. Treating all visible disease didn't stop new disease from appearing elsewhere. The visible tumors were never the whole story — they were the visible part of a systemic disease behaving systemically. This is the trial that should retire a reflex: "there's a spot, let's zap it." Local control is real. But local control is not systemic control, and conflating the two is how patients get toxicity without benefit. The carousel breaks down the trial design and what it actually proved. Swipe through. When the imaging shows you a target but the biology says otherwise — which one do you treat? #RadOnc #SBRT #ClinicalTrials #IR #InterventionalRadiology

In surgery, nobody trusts their memory. That's the whole point of the count. Every sponge, every needle, every instrument — counted in, counted out, reconciled before closure. Not because the team is careless. Because the team knows memory is the least reliable safety system ever designed. Radiation oncology has its own version of this discipline, and the best departments treat it the same way: independent plan checks, timeout verifications, daily image guidance. But here's what the OR gets right that too many clinics still treat as optional — the count is a CULTURE, not a checklist. A checklist can be pencil-whipped. A culture can't. In the OR, the circulator who stops the surgeon to reconcile a count isn't being difficult — they're being the system working as designed. The hierarchy flattens for the count. Rank doesn't outrank the sponge. Translate that to the linac: does your department's second checker have real authority to stop a plan? Or is the "independent check" a signature from someone who already knows what the first checker found? The principle travels cleanly across modalities: build the verification into the culture, give the verifier real power, and never trust memory where you can count instead. What does the "count" look like in your department? #RadOnc #PatientSafety #QualityAssurance #IR #InterventionalRadiology

Myth: irradiating a bigger area cures more cancer. For years, the logic felt airtight in high-risk prostate cancer: if microscopic disease hides in the pelvic lymph nodes, then whole-pelvic radiotherapy should beat prostate-only radiotherapy. Bigger field, more cancer killed, better survival. Intuition says yes. Five randomized trials and 5,172 patients say no. A new systematic review and meta-analysis pooled every phase 3 trial comparing whole-pelvic RT against prostate-only RT in clinically node-negative high-risk localized prostate cancer — RTOG 9413, GETUG-01, POP-RT, PEACE-2, and RTOG 0924: • Overall survival: NO improvement with whole-pelvic RT • The apparent benefits in biochemical and metastasis-free survival? Driven ENTIRELY by a single single-center trial. Exclude it, and the benefit vanishes. That last detail is the whole lesson. One outlier trial carried the entire narrative for years. Strip it out and the emperor has no field size. This doesn't mean pelvic nodal irradiation never helps anyone — but it does mean "bigger is better" was never evidence. It was geometry masquerading as oncology. The carousel walks through the five trials and where the signal actually came from. Swipe through. What other "obvious" oncology intuitions are waiting for their meta-analysis? #RadOnc #ProstateCancer #EvidenceBasedMedicine #IR #InterventionalRadiology

If your KOL meeting could have been an email, you weren't doing field medical. Controversial? Maybe. But here's the uncomfortable truth about scientific exchange: most of what passes for it is one-directional. A deck, a monologue, a "great discussion" that was really a presentation with questions at the end. Real field-medical work looks nothing like that: • The best insight of the meeting usually comes AFTER you close the laptop. The deck gets you in the room; the conversation after it is the actual job. • If you talked more than you listened, you failed — regardless of how good the slides were. Insights don't live in presentations. They live in the unguarded sentence a KOL says when they think the formal part is over. • A KOL who corrects you just gave you more value than one who agrees with you. Disagreement is data. Agreement is pleasant and useless. • The write-up matters more than the visit. An insight that isn't documented, contextualized, and routed to the right team within 24 hours didn't happen — it was a nice conversation. The deck is the least interesting thing in the room. It's the price of admission, not the product. Medical Affairs isn't measured in meetings held. It's measured in what the organization learned because you were in those rooms. What's the most valuable thing a KOL ever told you AFTER the slides were put away? #MedicalAffairs #FieldMedical #IR #InterventionalRadiology

Radiation therapy for... knee arthritis? Stay with me. At ASTRO 2026, researchers presented an integrated analysis of a completed randomized trial testing LOW-DOSE radiotherapy for early knee osteoarthritis — and the numbers demand attention: • 292 patients with symptomatic early knee OA, randomized to standard drugs alone vs. drugs + orthovoltage LDRT (4.5 Gy in 10 fractions) • Greater, more durable improvements in pain, physical function, and quality of life with LDRT • Less structural progression on MRI at 12 and 36 months — less cartilage deterioration, less bone marrow edema • Disability risk cut by two-thirds (adjusted HR 0.33); total knee replacements cut nearly in half (HR 0.51) • Biggest benefit in KL grade 2 disease: disability HR 0.37, knee replacement HR 0.32 Now the honest caveats, because this is how the field should talk about early data: • This is one integrated analysis from a Russian center (Northern State Medical University). It needs independent replication before anyone changes practice. • The mechanism — anti-inflammatory effect of low-dose radiation — is plausible but not proven here. • 4.5 Gy is a fraction of cancer-treatment doses, but "low dose" still means ionizing radiation for a non-malignant condition. The risk-benefit bar is, correctly, very high. Still: if treating inflammation early can change the course of a disease that ends in joint replacement, that's worth chasing — carefully. Where else is low-dose radiation being under-explored? #RadOnc #ASTRO26 #Osteoarthritis #IR #InterventionalRadiology

After brain metastasis surgery, one big radiation dose was the standard. As of ASTRO 2026, it shouldn't be. Alliance A071801 — the FIRST randomized phase 3 trial comparing single-fraction vs. fractionated stereotactic radiosurgery after resection of a large brain metastasis — just rewrote the postoperative playbook: • 242 patients, resected brain met > 2 cm (melanoma, lung, breast primaries most common) • 1-year surgical bed control: 87% (3–5 fractions) vs. 81% (single fraction) • Median overall survival: 29 months vs. 20 months — NINE months longer with fractionation • Side effects: no significant difference (radiation necrosis 14% vs. 10%, cerebral edema 8% vs. 9%) The survival difference caught even the investigators off guard — deaths were from systemic disease, not brain mets. As PI Paul Brown (Mayo Clinic) put it: "Something with brain control affects survival. We don't know quite what." What changes Monday morning: for resected large brain metastases, 3–5 fraction SRS should now be the default conversation, not the exception. As co-author Ayal Aizer (Dana-Farber) said, this moves fractionated SRS "from a reasonable practice supported by retrospective data to one backed by a randomised phase 3 trial." Better control. Longer survival. Same safety. That's not incremental — that's a new standard. Is your center's postoperative SRS protocol already there? #RadOnc #ASTRO26 #BrainMets #Neurosurgery #IR #InterventionalRadiology